Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury

Toxicological Sciences

Volumn 130, Issue 1, 2012, Pages 4-16

  Higuchi, Satonori ^a   Yano, Azusa ^a   Takai, Shohei ^a   Tsuneyama, Koichi ^b   Fukami, Tatsuki ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Carbamazepine; Hepatotoxicity; IL 17; Metabolism; Mouse model

Indexed keywords

3 HYDROXYCARBAMAZEPINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CALGRANULIN A; CALGRANULIN B; CARBAMAZEPINE; CYTOKINE; DRUG METABOLITE; FAS LIGAND; GAMMA INTERFERON; GLUTATHIONE; GLUTATHIONE DISULFIDE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; OXCARBAZEPINE; PROSTAGLANDIN E1; PROTEIN P19; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; IMMUNE RESPONSE; INFLAMMATION; INJURY SEVERITY; LIVER HISTOLOGY; LIVER INJURY; LIVER TOXICITY; MALE; METABOLIC ACTIVATION; MOUSE; NONHUMAN; OXIDATIVE STRESS;

ALANINE TRANSAMINASE; ALPROSTADIL; ANIMALS; ANTICONVULSANTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOTRANSFORMATION; CARBAMAZEPINE; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; FIBRINOLYTIC AGENTS; GLUTATHIONE; HEPATITIS; LIVER; MALE; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS;

EID: 84867771965     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs222     Document Type: Article

References (35)

1. Ahmed, S. N., and Siddiqi, Z. A. (2006). Antiepileptic drugs and liver disease. Seizure 15, 156-164.
2. Antoine, D. J., Williams, D. P., Kipar, A., Jenkins, R. E., Regan, S. L., Sathish, J. G., Kitteringham, N. R., and Park, B. K. (2009). High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 112, 521-531.
3. Björnsson, E., and Olsson, R. (2005). Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42, 481-489.
4. Björnsson, E. (2008). Hepatotoxicity associated with antiepileptic drugs. Acta Neurol. Scand. 118, 281-290.
5. Chavakis, T., Bierhaus, A., Al-Fakhri, N., Schneider, D., Witte, S., Linn, T., Nagashima, M., Morser, J., Arnold, B., Preissner, K. T., et al. (2003). The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J. Exp. Med. 198, 1507-1515.
6. Eichelbaum, M., Ekbom, K., Bertilsson, L., Ringberger, V. A., and Rane, A. (1975). Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur. J. Clin. Pharmacol. 8, 337-341.
7. Hung, S. I., Chung, W. H., Jee, S. H., Chen, W. C., Chang, Y. T., Lee, W. R., Hu, S. L., Wu, M. T., Chen, G. S., Wong, T. W., et al. (2006). Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297-306.
8. Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., and Lemasters, J. J. (2002). Mechanisms of hepatotoxicity. Toxicol. Sci. 65, 166-176.
9. Jin, H., Dai, J., Chen, X., Liu, J., Zhong, D., Gu, Y., and Zheng, J. (2009). Pulmonary toxicity and metabolic activation of dauricine in CD-1 mice. J. Pharmacol. Exp. Ther. 332, 738-746.
10. Kaufman, D. W., and Shapiro, S. (2000). Epidemiological assessment of drug-induced disease. Lancet 356, 1339-1343.
11. Kidd, P. (2003). Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8, 223-246.
12. Kita, H., Mackay, I. R., Van De Water, J., and Gershwin, M. E. (2001). The lymphoid liver: Considerations on pathways to autoimmune injury. Gastroenterology 120, 1485-1501.
13. Kobayashi, E., Kobayashi, M., Tsuneyama, K., Fukami, T., Nakajima, M., and Yokoi, T. (2009). Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci. 111, 302-310.
14. Kobayashi, M., Higuchi, S., Mizuno, K., Tsuneyama, K., Fukami, T., Nakajima, M., and Yokoi, T. (2010). Interleukin-17 is involved in alpha-naphthylisothiocyanate-induced liver injury in mice. Toxicology 275, 50-57.
15. Kumada, T., Tsuneyama, K., Hatta, H., Ishizawa, S., and Takano, Y. (2004). Improved 1-h rapid immunostaining method using intermittent microwave irradiation: Practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod. Pathol. 17, 1141-1149.
16. Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., and Cua, D. J. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240.
17. Lertratanangkoon, K., and Horning, M. G. (1982). Metabolism of carbamazepine. Drug Metab. Dispos. 10, 1-10.
18. Lotze, M. T., Zeh, H. J., Rubartelli, A., Sparvero, L. J., Amoscato, A. A., Washburn, N. R., Devera, M. E., Liang, X., Tör, M., and Billiar, T. (2007). The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 220, 60-81.
19. Lu, W., and Uetrecht, J. P. (2008). Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin. Drug Metab. Dispos. 36, 1624-1636.
20. Mu, H. H., Hasebe, A., Van Schelt, A., and Cole, B. C. (2011). Novel interactions of a microbial superantigen with TLR2 and TLR4 differentially regulate IL-17 and Th17-associated cytokines. Cell. Microbiol. 13, 374-387.
21. Novartis Pharma Co. (2011). Interview Form (Product Information Booklet) of Tegretol®, 9th ed. Novartis Pharma Co., Tokyo, Japan.
22. Oo, Y. H., and Adams, D. H. (2009). The role of chemokines in the recruitment of lymphocytes to the liver. J. Autoimmun. 34, 45-54.
23. Oscarson, M., Zanger, U. M., Rifki, O. F., Klein, K., Eichelbaum, M., and Meyer, U. A. (2006). Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther. 80, 440-456.
24. Park, B. K., Kitteringham, N. R., Powell, H., and Pirmohamed, M. (2000). Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 153, 39-60.
25. Pearce, R. E., Lu, W., Wang, Y., Uetrecht, J. P., Correia, M. A., and Leeder, J. S. (2008). Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab. Dispos. 36, 1637-1649.
26. Pearce, R. E., Vakkalagadda, G. R., and Leeder, J. S. (2002). Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab. Dispos. 30, 1170-1179.
27. Pellinen, P., Honkakoski, P., Stenbäck, F., Niemitz, M., Alhava, E., Pelkonen, O., Lang, M. A., and Pasanen, M. (1994). Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur. J. Pharmacol. 270, 35-43.
28. Pirmohamed, M., Kitteringham, N. R., Breckenridge, A. M., and Park, B. K. (1992a). Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br. J. Clin. Pharmacol. 33, 183-186.
29. Pirmohamed, M., Kitteringham, N. R., Guenthner, T. M., Breckenridge, A. M., and Park, B. K. (1992b). An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem. Pharmacol. 43, 1675-1682.
30. Savov, J. D., Brass, D. M., Lawson, B. L., McElvania-Tekippe, E., Walker, J. K., and Schwartz, D. A. (2005). Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am. J. Physiol. Lung Cell Mol. Physiol. 289, L329-L337.
31. Steinman, L. (2007). A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13, 139-145.
32. Sugawara, Y., Kubota, K., Ogura, T., Esumi, H., Inoue, K., Takayama, T., and Makuuchi, M. (1998). Protective effect of prostaglandin E1 against ischemia/reperfusion-induced liver injury: Results of a prospective, randomized study in cirrhotic patients undergoing subsegmentectomy. J. Hepatol. 29, 969-976.
33. Talpain, E., Armstrong, R. A., Coleman, R. A., and Vardey, C. J. (1995). Characterization of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophils. Br. J. Pharmacol. 114, 1459-1465.
34. Wang, H., Yang, H., and Tracey, K. J. (2004). Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med. 255, 320-331.
35. Yao, D., and Brownlee, M. (2010). Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59, 249-255.